Metraipolis › archive › dc_cd806dfe01de

Cost-effectiveness analysis of nab-paclitaxel with or without relacorilant for platinum-resistant ovarian cancer — Europe PMC PMID:42021384

Source: Europe PMC (en)
Original: https://europepmc.org/article/MED/42021384
DOI: 10.1186/s13048-[numero omesso]-7
License (as archived): solo-consultazione
Archived: 2026-11-03T07:39:44.347Z
SHA-256 of the archived text: e7ca2201d131f248f10de2e773b5e8f9d14084ebc50d1eca7886ea963bfbdbe8
Stable URL of this page: https://metraipolis.com/documento/dc_cd806dfe01de

How to cite

Cost-effectiveness analysis of nab-paclitaxel with or without relacorilant for platinum-resistant ovarian cancer — Europe PMC PMID:42021384 — Europe PMC (en), https://europepmc.org/article/MED/42021384 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_cd806dfe01de (Metraipolis archive dc_cd806dfe01de, sha256 e7ca2201d131f248f10de2e773b5e8f9d14084ebc50d1eca7886ea963bfbdbe8)

BibTeX

@misc{dccd806dfe01de,
  title = {Cost-effectiveness analysis of nab-paclitaxel with or without relacorilant for platinum-resistant ovarian cancer — Europe PMC PMID:42021384},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42021384},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_cd806dfe01de; sha256 e7ca2201d131f248f10de2e773b5e8f9d14084ebc50d1eca7886ea963bfbdbe8},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42021384. Agents can read the archived copy with the MCP tool read_document.